Interim Report: Inotuzumab Ozogamicin + Bosutinib in R/R Ph+ ALL or CML in Lymphoid Blast Phase

Slideset - Review promising preliminary findings from a phase I/II trial assessing combination therapy with inotuzumab ozogamicin and bosutinib in patients with relapsed/refractory Philadelphia chromosome –positive ALL or CML in lymphoid blast phase.

Source: Clinical Care Options Leukemia - December 12, 2017 Category: Hematology Source Type: research